PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Completes Annual General Meeting
March 01, 2023 08:00 ET | PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
OptimiTM-03.jpg
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
March 01, 2023 07:30 ET | Optimi Health Corp.
Highlights:  Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
Full Logo - OKYO .jpg
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023 02:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
February 14, 2023 08:00 ET | PharmAla Biotech
VANCOUVER, British Columbia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that, in the wake of a landmark decision by the...
02_Technicians at the new Dipharma CGMP warehouse in the Kalamazoo site
Dipharma completes second phase of CGMP expansion at its Kalamazoo site
February 10, 2023 10:29 ET | Dipharma Francis S.r.l
MILAN, Italy, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a global CDMO and leading manufacturer of Active Pharmaceutical Ingredients and advanced Intermediates, announced...
22157.jpg
One Month Remains to Register for the cGMP Regulatory Inspections Course - Through the Eyes of FDA, EMA and PMDA (March 7, 2023)
February 06, 2023 05:43 ET | Research and Markets
Dublin, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The "cGMP Regulatory Inspections - Through the Eyes of FDA, EMA and PMDA" training has been added to ResearchAndMarkets.com's offering. GMP-compliance is...
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023 00:01 ET | PharmAla Biotech
VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...
22157.jpg
2 Day Online Course on Aseptic Processing in the Manufacture of Pharmaceutical and Biotech Products (February 2-3, 2023)
December 30, 2022 04:58 ET | Research and Markets
Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "2 Day Course on Aseptic Processing in the Manufacture of Pharmaceutical and Biotech Products 22" training has been added to ResearchAndMarkets.com's...
22157.jpg
Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment: 2 Day Issues and Solutions Training Course (January 23-24, 2023)
December 30, 2022 04:38 ET | Research and Markets
Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course" training has been added to ...
Logo DIPHARMA.jpg
Dipharma receives GMP certification from Brazilian ANVISA
December 01, 2022 08:46 ET | Dipharma Francis S.R.L
MILAN, Italy, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active...